 |
 |
 | |
 |
 |
||
 |
September 2006 - Issue E047 Welcome to the September edition of NICE's monthly E-newsletter.  |
||
 |
 | |
 |
New NICE guidelines to improve care for patients with anaemia linked to chronic kidney disease more>> |
|
 |
||
|
A round-up of clinical guidance documents that NICE has issued and consulted on during September more>> |
| |
 |
||
| Public health evidence documents that NICE has issued during September more>> | ||
 |
||
| An update on new support for implementation more>> | ||
 |
||
|
New NICE guidance to improve care for early breast cancer more>> NICE recommends rituximab for the first line treatment of follicular lymphoma more>> NICE welcomes bigger role in topic selection process more>> NICE welcomes new initiative to help NHS reduce spending on treatments that do not improve patient care more>> NICE welcomes referral of new work programme topics more>> |
||
 |
||
| Upcoming events more>> | ||
 |
||
| Guidance and consultation papers expected to be issued next month more>> | ||
 |
||
| NICE is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health. more>> | ||
|
About the E-Newsletter
|
||
 |
||||||||||||||||
 |
New NICE guidelines to improve care for patients with anaemia linked to chronic kidney disease
The National Institute for Health and Clinical Excellence (NICE)
and the National Collaborating Centre for Chronic Conditions have
today (27 September) published a clinical guideline to improve
treatment and care for people with anaemia associated with chronic
kidney disease. The new guideline advises on the detection and diagnosis of
anaemia in people with chronic kidney disease, effective treatments,
when treatment for anaemia should start, and how clinicians and
patients should create a joint treatment plan A key recommendation is that age alone should not be a
determinant for treatment of anaemia of chronic kidney disease. The
guideline sets out target haemoglobin (Hb) levels in both adults and
children, and levels of Hb at which specified therapies should be
given. It also provides detailed advice on initiating, administering
and adjusting for erythropoiesis-stimulating agent (ESA) treatment
as appropriate. Professor Peter Littlejohns, Clinical
and Public Health Director at NICE and Executive Lead for the
guideline, said: “This guideline will help improve the care
and treatment of people with anaemia linked to chronic kidney
disease. It provides recommendations for supporting patients, by
providing information about anaemia of CKD, practical advice on
managing their condition and access to a contact who will coordinate
their treatment and care. It also gives clear best practice advice
to health professionals on the most effective way to provide care,
and our implementation advice will support that delivery.” More
information is available on the NICE website. |
 | ||||||||||||||
|
|
||||||||||||||||
 |
||||||||||||||||
|
A round-up of clinical guidance documents that NICE has issued and consulted on during September
NICE issued the following guidance this month:
Guidelines Technology appraisals Interventional procedures Public health The following consultation documents were issued:
Guidelines Calls for stakeholder registration: Scope consultations: Draft consultations: Technology appraisals ACD consultations: FAD consultations: Appeals heard: Interventional procedures NICE consulted on the following procedures
(consultation period 29 August to 26 September) Public health Calls for stakeholder registration: Stakeholder meeting: Scope consultations: Final scope: Consultation on draft recommendations: Consultation on synopsis of evidence:
|
||||||||||||||||
|
|
||||||||||||||||
 |
||||||||||||||||
|
Public health evidence documents that NICE has issued during September
No publications have been issued this month.
|
||||||||||||||||
|
|
||||||||||||||||
|
||||||||||||||||
|
|
||||||||||||||||
|
||||||||||||||||
|
An update on new support for implementation
Welcome to the implementation section, featuring updates on
current work, new resources to support implementation and products
coming soon. The implementation website section is at: http://www.nice.org.uk/implementation.
Anaemia management in chronic kidney disease
Breast cancer (early) - docetaxel Non-Hodgkin's lymphoma - rituximab Several electronic costing reports and local cost templates will
be published soon to support forthcoming NICE appraisals on
permetrexed disodium for mesothelioma and inhaled insulin for type 1
and 2 diabetes and the clinical guideline update for familial breast
cancer. A slide set, implementation advice and costing tools will be
published soon to support the forthcoming NICE guideline on urinary
incontinence. NICE have commissioned the BMJ to produce interactive online
educational tools to support NICE guidance on smoking cessation
interventions, epilepsy, anxiety and depression and
tuberculosis. NICE field-based Implementation Consultants are approaching all
NHS organisations via the Chief Executive offices, to provide a
personal update and receive feedback. Web-based good practice commissioning guides will be available
from the NICE website this autumn on the following topics: They set benchmarks to determine the level of service needed for
a particular topic, link to other sources of information and offer
advice on a range of issues, including local needs assessment and
opportunities for disinvestment. We are seeking examples of how NICE guidance has been put into
practice to add to our new online database which will be available
in the autumn. The purpose of this is to share your experiences that
might help others. Visit our website
for information.
|
||||||||||||||||
|
|
||||||||||||||||
 |
||||||||||||||||
|
NICE has today issued guidance to the NHS on the use of docetaxel
and paclitaxel for the treatment of early breast cancer following
surgery. NICE has recommended that: Andrea Sutcliffe, Deputy Chief Executive at NICE and
Executive Lead for this appraisal, said: “ NICE has issued
clear advice to the NHS on the use of docetaxel and paclitaxel for
early breast cancer following surgery which will give the best care
to patients and use NHS resources most effectively. This is the
latest guidance to be developed using the new NICE rapid appraisal
process, and we hope to continue to assess individual drugs quickly
to provide robust guidance to the NHS close to when they are
licensed ” More information is available on the NICE website. NICE has today issued guidance to the NHS in England in Wales
recommending rituximab, within its licensed indications, (that is,
in combination with cyclophosphamide, vincristine and prednisolone -
or CVP) as an option for the treatment of patients with symptomatic
stage III and IV follicular lymphoma who have previously been
untreated. Dr Gillian Leng, Implementation Systems Director and
Executive Lead for the appraisal, said: “In 2002 NICE
issued guidance recommending the use of rituximab as last-line
treatment of stage III or IV follicular lymphoma. Today’s guidance
extends the use of this drug to cover first-line treatment, improves
the options available to people with this form of cancer and sets
clear standards for the NHS in England and Wales on how it should be
used .” More information is
available on the NICE website. NICE has welcomed the Department of Health announcement that NICE
will play a bigger role in the topic selection process. Topics are
the specific treatments, drugs or ways of caring for people with
specific conditions or diseases, preventing ill health or promoting
good health about which NICE will provide guidance for the NHS and
the wider public health community. The Department of Health today confirmed that NICE will be
responsible for the administration of the early stages of topic
selection, as well as the organisation of seven new independent
consideration panels. The panels will recommend to the Department of
Health which topics NICE should produce guidance on. Ministers will
continue to make the final decision on which topics are referred to
NICE for guidance production. Andrea Sutcliffe, Deputy Chief Executive at NICE, said:
“We welcome these changes to the topic selection process -
NICE’s increased role should help the process operate more
efficiently, allowing us to start working on topics suggested more
quickly, and so produce guidance on selected topics earlier. “As well as administering the early part of the selection
process, we’re also responsible for setting up a range of
independent topic selection consideration panels. We are keen to
encourage people to contribute to the guidance production process by
continuing to suggest topics.” More
information is available on the NICE website. NICE welcomed the announcement by Health Minister Andy Burnham
asking NICE to launch a new programme of work to help the NHS
identify interventions that are not effective. NICE will develop a new set of products to help the NHS make
better use of its resources by reducing spending on ineffective
treatments, that is, treatments that do not improve patient care or
do not represent good value for money. Moving away from ineffective
practice will save money that the NHS can invest in drugs and
approaches to care that make a positive difference to patients’
lives. Commenting on the announcement, NICE Chief Executive
Andrew Dillon stated: “NICE already advises the NHS on when it should invest in new
drugs and treatments that work well for patients. It’s common sense
for us to also advise the NHS on when it is appropriate to stop
using treatments that don’t benefit patients or do not represent
good value for money where there are better alternatives available.
I would like to encourage anyone who has suggestions for topics
that NICE should consider to let us know.” More
information is available on the NICE website. NICE has welcomed the referral of additional topics for its
forward work programme. Topics referred by the Secretary of State
for Health to NICE include eight further public health topics in
line with the Institute’s widened remit to include developing
guidance on promoting good health and preventing and treating ill
health. In addition, eleven technology appraisal topics have been
referred, and the remits fortwo of the nine
clinical guidelines topics referred in November 2005 have been
amended. Commenting on the referrals, Andrew Dillon, NICE Chief
Executive said: “We welcome the referral of new topics
across our work programmes, including the range of public health
topics. We will begin work on all the topics as soon as possible and
we will make detailed timetables available on our website
shortly.” A list of the
topics referred is available on the NICE website.
|
||||||||||||||||
|
|
||||||||||||||||
 |
||||||||||||||||
|
Upcoming events
The 2006 annual NICE conference will take place from 6 to 7
December at the ICC in Birmingham. ‘NICE 2006: Tackling health priorities’ will explore issues
raised by the increasing expectations of the public and politicians
in the context of finite resources, and the challenges facing
decision-makers at all levels of the health and social care sectors
in using evidence to inform their decisions and in justifying the
choices that they make. The conference programme is now available on the NICE
website and information on the registration is on the conference
website The Royal College of Obstetricians and Gynaecologists (RCOG) and
the National Collaborating Centre for Women and Children’s Health
are holding an educational day to coincide with the forthcoming NICE
guideline on urinary incontinence in women. The day is for health
professionals and patients groups, and takes place on Friday 27th
October More
information is available on the RCOG website or by calling the
RCOG Conference Office on 020 7772 6245. This joint one-day conference by the Royal College of Physicians
and The British Thoracic Society will discuss recent major changes
in the NHS’s approach to controlling TB. The NICE
guidelines on tuberculosis, published in March 2006, will be one
of the developments discussed. Taking place on Monday 16th October,
the conference is for clinical and public health professionals. More
information is available on the RCP website.. |
||||||||||||||||
|
|
||||||||||||||||
 |
||||||||||||||||
|
NICE expects to issue the following guidance: Clinical guidelines Technology appraisals Interventional procedures Public health NICE expects to publish the following evidence documents:
NICE expects to issue draft consultation documents on: Calls for stakeholder registration: Draft consultations: Scope consultations: None NICE expects to issue consultation documents on: ACDs to be published: FADs to be published: Appeals to be heard: None NICE will consult on the following procedures (consultation
period 26 September to 24 October ) : NICE expects to issue consultation documents on: Call for stakeholder registration: Scope consultations: Stakeholder meetings: Final scope : Consultation on synopsis of evidence: Consultation on draft recommendations : |
||||||||||||||||
|
|
||||||||||||||||
 |
||||||||||||||||
|
The National Institute for Health and
Clinical Excellence (NICE) is the independent organisation
responsible for providing national guidance on the promotion of good
health and the prevention and treatment of ill health. Click here for
the NICE website Click here to unsubscribe from the E-newsletter Click here to register for the E-newsletter Click here to contact NICE
regarding general queries Click here to provide
feedback on the E-newsletter |
||||||||||||||||
|
|
||||||||||||||||
 | ||||||||||||||||